California

PROVIDER*Update*

CONTRACTUAL

AUGUST 27, 2019

UPDATE 19-667

1 PAGE

Prior Authorization Requirements Updates

Changes for Zolgensma[®] medication and other requirements

Zolgensma – FDA newly approved medication

The U.S. Food and Drug Administration (FDA) approved Zolgensma on May 24, 2019. Effective immediately, Zolgensma requires prior authorization (PA). Zolgensma is used to treat pediatric patients under age two with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

View authorization requirements online

Follow the steps below to find out if prior authorization is needed for any procedures, services or equipment:

- 1 Go to provider.healthnet.com
- 2 Before logging in, select *Working with Health Net > Policies for Non-Contracting Providers > Additional Resources > Services Requiring Prior Authorization.*
- 3 After logging in, select *Working with Health Net* > *Contractual* > *Services Requiring Prior Authorization.*

Additional information

Providers are encouraged to access Health Net's* provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.



- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

provider_services@healthnet.com Los Angeles County – 1-855-464-3571 San Diego County – 1-855-464-3572 www.healthnet.com

PROVIDER COMMUNICATIONS provider.communications@ healthnet.com

^{*} Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments. OTH034539EW00 (8/19)